SAB Biotherapeutics, Inc. (SABS), Monday announced its partnership with Naval Medical Research Centre to develop a therapy, named SAB-176, which can be used as a pre- and post-exposure prophylactic treatment for influenza type A and type B.
Influenza is a highly contagious infection of respiratory passages caused by a virus.
Under the Cooperative Research and Development Agreement, both the parties will conduct a pharmacokinetic, safety and tolerability study of the therapy.
The company has utilized its proprietary DiversitAb platform to manufacture SAB-176, fully human polyclonal antibodies targeting influenza from Transchromosomic Bovine.
Last year, the U.S. Food and Drug Administration had granted Breakthrough Therapy and Fast Track Designations to SAB-176 based on the positive outcome from the clinical proof-of-concept Phase 2 study in an influenza challenge model with intravenous formulation.
Currently, SAB's stock is sliding 4.81 percent, to $4.645 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.